source
- uniQure shares tumble 41% after Huntington’s gene therapy misses primary endpointuniQure reported updated 48‑month data from its phase 1/2 trial of AMT‑130 in Huntington’s disease. The therapy showed a 44% slowing of disease progression on the composite Unified Huntington’s Dis…
- FDA approves Egetis Therapeutics' Emcitate for rare X linked disease shortening life expectancy to 35 yearsEgetis Therapeutics announced that the U.S. Food and Drug Administration has granted approval for its drug Emcitate. The therapy is intended for patients with a rare X linked genetic disorder that…